Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wolters Kluwer full text link Wolters Kluwer Free PMC article
Full text links

Actions

Share

Review
.2011 Oct;22(10):1795-803.
doi: 10.1681/ASN.2011050464. Epub 2011 Sep 23.

The pathophysiology of IgA nephropathy

Affiliations
Review

The pathophysiology of IgA nephropathy

Hitoshi Suzuki et al. J Am Soc Nephrol.2011 Oct.

Abstract

Here we discuss recent advances in understanding the biochemical, immunologic, and genetic pathogenesis of IgA nephropathy, the most common primary glomerulonephritis. Current data indicate that at least four processes contribute to development of IgA nephropathy. Patients with IgA nephropathy often have a genetically determined increase in circulating levels of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1). This glycosylation aberrancy is, however, not sufficient to induce renal injury. Synthesis and binding of antibodies directed against galactose-deficient IgA1 are required for formation of immune complexes that accumulate in the glomerular mesangium (Hits 2 and 3). These immune complexes activate mesangial cells, inducing proliferation and secretion of extracellular matrix, cytokines, and chemokines, which result in renal injury (Hit 4). Recent genome-wide association studies identify five distinct susceptibility loci--in the MHC on chromosome 6p21, the complement factor H locus on chromosome 1q32, and in a cluster of genes on chromosome 22q22--that potentially influence these processes and contain candidate mediators of disease. The significant variation in prevalence of risk alleles among different populations may also explain some of the sizable geographic variation in disease prevalence. Elucidation of the pathogenesis of IgA nephropathy provides an opportunity to develop disease-specific therapies.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Human IgA1: hinge-region amino acid sequence (A) and possible glycan variants (B). (A) IgA1 contains up to sixO-glycans per hinge region: five major sites are shown (in orange or magenta) and the sixth site is Thr233. Novel approaches using IgA-specific bacterial proteases and lectin binding, and, more recently, high-resolution mass spectrometry with electron capture and electron transfer dissociation, have been used to determineO-glycan heterogeneity, the sites of glycosylation, and the microheterogeneity at the individual sites.,,,, The model of intact IgA1 was generated from published crystal and solution structures of IgA1.,N- andO-glycans were modeled using the GlyProt server and related databases (http://www.glycosciences.de), based on observed IgA1 glycoforms., For clarity, theO-glycans are shown with transparent spheres for each atom, and are colored orange for GalNAc-galactose residues and magenta for GalNAc; the illustratedO-glycan distribution was taken from a study by Takahashiet al. (B) The variants ofO-glycans on circulatory IgA1. Galactose-deficient glycans present in elevated amounts in patients with IgAN are represented by structures I and II in magenta., Galactosylated variants are in orange as structures III to VI. The largestO-glycan on circulatory IgA1 is a GalNAc-galactose with two sialic acids,i.e., tetrasaccharide, structure VI. IgA1 with GalNAc and sialylated GalNAc (structures I and II in magenta) is present at elevated serum levels in patients with IgAN due to the changes in expression and activity of specific glycosyltransferases, ST6GalNAcII, and C1GalT1. The stability of C1GalT1 during translation is controlled by Cosmc, a foldase. Structure I is generated by a GalNAc-transferase; structure II, by ST6GalNAcII; structure III, from structure I by C1GalT1; and structures IV to VI, by sialyltransferases. Symbols: rectangle, GalNAc; circle, galactose; diamond, sialic acid.
Figure 2.
Figure 2.
Proposed pathways involved in the pathogenesis of IgAN: multi-hit mechanism. Hit 1: Production of galactose-deficient IgA1 by a subpopulation of IgA1-secreting cells. IgA1 production may be affected by the IgAN-associated locus on chromosome 22q12.2. Hit 2: Formation of anti-glycan antibodies with specific characteristics of the variable region of the heavy chain that recognize galactose-deficient IgA1. Hit 3: Formation of immune complexes from autoantigen (galactose-deficient IgA1) andO-glycan-specific antibodies. Hits 2 and 3 may be regulated by the three MHC loci on chromosome 6p21 associated with risk of IgAN. Hit 4: Deposition of pathogenic immune complexes in the mesangium, activation of mesangial cells, and induction of glomerular injury. Hits 3 and 4 may be affected by genotype at the complement factor H locus on chromosome 1q32 that regulates the alternative complement cascade. The first pathway assumes formation of immune complexes in the circulation and their subsequent mesangial deposition (solid lines).,,, An alternative theory proposes that some of the aberrantly glycosylated IgA1 molecules are in the mesangium as lanthanic deposits (left broken line) and are later bound by newly generated anti-glycan antibodies to form immune complexesin situ (right broken line) that activate mesangial cells. ECM, extracellular matrix.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Berger J, Hinglais N: Les dépôts intercapillaires d'IgA-IgG (Intercapillary deposits of IgA-IgG). J Urol Nephrol 74: 694–695, 1968 - PubMed
    1. Silva FG, Chander P, Pirani CL, Hardy MA: Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33: 241–246, 1982 - PubMed
    1. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP: Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43: 321–327, 2011 - PMC - PubMed
    1. Coppo R, Feehally J, Glassock RJ: IgA nephropathy at two score and one. Kidney Int 77: 181–186, 2010 - PubMed
    1. Mestecky J, Moro I, Kerr MA, Woof JM: Mucosal immunoglobulins. In: Mucosal Immunology, 3rd ed, edited by Mestecky J, Bienenstock J, Lamm ME, Mayer L, McGhee JR, Strober W. Amsterdam, Elsevier Academic Press, 2005, pp 153–181

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wolters Kluwer full text link Wolters Kluwer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp